Free Trial
NASDAQ:CING

Cingulate Q2 2024 Earnings Report

Cingulate logo
$4.07 -0.25 (-5.79%)
Closing price 04:00 PM Eastern
Extended Trading
$4.14 +0.07 (+1.84%)
As of 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cingulate EPS Results

Actual EPS
-$5.47
Consensus EPS
-$5.64
Beat/Miss
Beat by +$0.17
One Year Ago EPS
N/A

Cingulate Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cingulate Announcement Details

Quarter
Q2 2024
Time
Before Market Opens
Conference Call Date
Tuesday, August 13, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Cingulate's Q1 2025 earnings is scheduled for Wednesday, May 14, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Cingulate Earnings Headlines

Roth MKM Sticks to Their Buy Rating for Cingulate Inc (CING)
Trump wipes out trillions overnight…
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.
See More Cingulate Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cingulate? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cingulate and other key companies, straight to your email.

About Cingulate

Cingulate (NASDAQ:CING), a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

View Cingulate Profile

More Earnings Resources from MarketBeat